A. Omuro and L. M. Deangelis, Glioblastoma and other malignant gliomas: a clinical review, JAMA, vol.310, issue.17, pp.1842-1850, 2013.

M. R. Gilbert, M. Wang, and K. D. Aldape, Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, J Clin Oncol, vol.31, issue.32, pp.4085-4091, 2013.

A. A. Thomas, C. W. Brennan, L. M. Deangelis, and A. M. Omuro, Emerging therapies for glioblastoma, JAMA Neurol, vol.71, issue.11, pp.1437-1444, 2014.

M. A. Dawson and T. Kouzarides, Cancer epigenetics: from mechanism to therapy, Cell, vol.150, issue.1, pp.12-27, 2012.

S. B. Baylin and P. A. Jones, A decade of exploring the cancer epigenome -biological and translational implications, Nat Rev Cancer, vol.11, issue.10, pp.726-734, 2011.

C. Baer, R. Claus, and C. Plass, Genome-wide epigenetic regulation of miRNAs in cancer, Cancer Res, vol.73, issue.2, pp.473-477, 2013.

A. Lujambio, C. Ga, and A. Villanueva, A microRNA DNA methylation signature for human cancer metastasis, Proc Natl Acad Sci, vol.105, issue.36, pp.13556-13561, 2008.

T. M. Malta, C. F. De-souza, and T. S. Sabedot, Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications, Neuro Oncol, vol.20, issue.5, pp.608-620, 2017.

A. A. Yin, N. Lu, and A. Etcheverry, A novel prognostic six-CpG signature in glioblastomas, CNS Neurosci Ther, vol.24, pp.167-177, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01711026

C. Brennan, R. Verhaak, and A. Mckenna, The somatic genomic landscape of glioblastoma, Cell, vol.155, issue.2, pp.462-477, 2013.

S. Kurscheid, P. Bady, and D. Sciuscio, Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma, Genome Biol, vol.16, p.16, 2015.

M. Ceccarelli, F. Malta, and T. , Molecular profiling reveals biologically discrete subsets and pathwaBarthelys of progression in diffuse glioma, Cell, vol.164, issue.3, pp.550-563, 2016.

M. J. Van-den-bent, L. Erdem-eraslan, and A. Idbaih, MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951, Clin Cancer Res, vol.19, issue.19, pp.5513-5522, 2013.

H. Noushmehr, D. J. Weisenberger, and K. Diefes, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell, vol.17, issue.5, pp.510-522, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01201573

P. Bady, D. Sciuscio, and A. Diserens, MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status, Acta Neuropathol, vol.124, issue.4, pp.547-560, 2012.

W. E. Johnson, C. Li, and A. Rabinovic, Adjusting batch effects in microarray expression data using empirical Bayes methods, Biostatistics, vol.8, issue.1, pp.118-127, 2007.

P. Du, X. Zhang, and C. Huang, Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis, BMC Bioinformatics, vol.11, p.587, 2010.

A. A. Alizadeh, A. J. Gentles, and A. J. Alencar, Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment, Blood, vol.118, issue.5, pp.1350-1358, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00743991

I. S. Lossos, D. K. Czerwinski, and A. A. Alizadeh, Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes, N Engl J Med, vol.350, issue.18, pp.1828-1837, 2004.

A. Subramanian, P. Tamayo, and V. K. Mootha, Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles, Proc Natl Acad Sci, vol.102, issue.43, pp.15545-15550, 2005.

S. M. Peterson, J. A. Thompson, M. L. Ufkin, P. Sathyanarayana, L. Liaw et al., Common features of microRNA target prediction tools, Frontiers in genetics, vol.5, p.23, 2014.

H. Mi, A. Muruganujan, D. Ebert, X. Huang, and P. D. Thomas, PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools, Nucleic Acids Res, vol.47, issue.D1, pp.419-426, 2019.

G. Bindea, J. Galon, and B. Mlecnik, CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data, Bioinformatics, vol.29, issue.5, pp.661-663, 2013.

G. Bindea, B. Mlecnik, and H. Hackl, ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks, Bioinformatics, vol.25, issue.8, pp.1091-1093, 2009.

J. K. Joo, S. H. Kim, and H. G. Kim, CpG methylation of transcription factor 4 in gastric carcinoma, Ann Surg Oncol, vol.17, issue.12, pp.3344-3353, 2010.

L. G. Rodriguez, X. Wu, and J. L. Guan, Wound-healing assay, Methods Mol Biol, vol.294, pp.23-29, 2005.

S. P. Weathers and J. De-groot, Resistance to antiangiogenic therapy, Curr Neurol Neurosci Rep, vol.14, issue.5, p.443, 2014.

K. M. Field, J. T. Jordan, P. Y. Wen, M. A. Rosenthal, and D. A. Reardon, Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies, Cancer, vol.121, issue.7, pp.997-1007, 2015.

R. J. Diaz, S. Ali, M. G. Qadir, D. La-fuente, M. I. Ivan et al., The role of bevacizumab in the treatment of glioblastoma, J Neurooncol, vol.133, issue.3, pp.455-467, 2017.

J. Li, H. Jin, H. Yu, B. Wang, and J. Tang, miRNA1284 inhibits cell growth and induces apoptosis of lung cancer cells, Mol Med Rep, vol.16, issue.3, pp.3049-3054, 2017.

W. Cao, W. Wei, Z. Zhan, Y. Xie, and Q. Xiao, MiR-1284 modulates multidrug resistance of gastric cancer cells by targeting EIF4A1, Oncol Rep, vol.35, issue.5, pp.2583-2591, 2016.

C. Pan, D. Wang, Y. Zhang, and W. Yu, MicroRNA-1284 inhibits cell viability and induces apoptosis of ovarian cancer cell line OVCAR3, Oncol Res, vol.24, issue.6, pp.429-435, 2016.

S. K. Tilley, W. Y. Kim, and R. C. Fry, Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies GRIA1 as a prognostic biomarker for basal-like bladder cancer, Am J Cancer Res, vol.7, issue.9, pp.1850-1862, 2017.

X. Yang, H. Han, D. Carvalho, D. D. Lay, F. D. Jones et al., Gene body methylation can alter gene expression and is a therapeutic target in cancer, Cancer Cell, vol.26, issue.4, pp.577-590, 2014.

Q. Liu, F. Liao, and H. Wu, Upregulation of miR-132 expression in glioma and its clinical significance, Tumour Biol, vol.35, issue.12, pp.12299-12304, 2014.

N. R. Parker, N. Correia, B. Crossley, M. E. Buckland, V. M. Howell et al., Correlation of MicroRNA 132 up-regulation with an unfavorable clinical outcome in patients with primary glioblastoma multiforme treated with radiotherapy plus concomitant and adjuvant temozolomide chemotherapy, Transl Oncol, vol.6, issue.6, pp.742-748, 2013.

G. Song and L. Wang, A conserved gene structure and expression regulation of miR-433 and miR-127 in mammals, PLoS One, vol.4, issue.11, p.7829, 2009.

H. Jiang, D. Hua, and J. Zhang, MicroRNA-127-3p promotes glioblastoma cell migration and invasion by targeting the tumor-suppressor gene SEPT7, Oncol Rep, vol.31, issue.5, pp.2261-2269, 2014.

D. Hua, F. Mo, and D. Ding, A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing, OMICS, vol.16, issue.12, pp.690-699, 2012.

S. Sun, X. Wang, and X. Xu, MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma, Oncotarget, vol.8, issue.3, pp.5057-5068, 2017.